XPro1595 (peganerst alfa)

TargetsTNF

Modalitysoluble TNF inhibitor

IndicationAlzheimer's disease

PhasePhase 1 (Completed)

PartnerNone

Trial IDNCT03943264

Notes

XPro1595 is a dominant-negative protein that specifically neutralizes soluble TNF without affecting trans-membrane TNF, selectively dampening microglial neuroinflammation while preserving immune function.

Source

Program entries are factual summaries of publicly disclosed clinical programs. Microglia.ai does not imply predictions about therapeutic outcomes or investment advice.

Last reviewed: June 3, 2026